IBEX trades 43.7% above Wall Street's consensus target of $24.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IBEX achieves its forward estimates and maintains a stable P/E multiple of 12.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, IBEX Limited (IBEX) has a Wall Street consensus price target of $24.00, based on estimates from 6 covering analysts. With the stock currently trading at $42.66, this represents a potential downside of -43.7%. The company has a market capitalization of $575M.
Analyst price targets range from a low of $20.00 to a high of $29.00, representing a 38% spread in expectations. The median target of $23.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IBEX trades at a trailing P/E of 18.1x and forward P/E of 12.1x. The forward PEG ratio of 0.30 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +13.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $49.74, with bear and bull scenarios of $31.33 and $65.53 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
TTECTTEC Holdings, Inc. | $60M | $1.23 | $34.17 | +2678.0% | Hold | 1.1x | 14 |
CNXCConcentrix Corporation | $1.8B | $30.21 | $35.00 | +15.9% | Buy | 2.8x | 9 |
TASKTaskUs, Inc. | $759M | $8.41 | $9.33 | +10.9% | Buy | 6.3x | 11 |
TLYSTilly's, Inc. | $124M | $4.13 | $5.50 | +33.2% | Hold | — | 17 |
EPAMEPAM Systems, Inc. | $5.8B | $110.06 | $119.00 | +8.1% | Buy | 8.4x | 37 |
CTSHCognizant Technology Solutions Corporation | $26.6B | $59.14 | $64.25 | +8.6% | Hold | 10.3x | 51 |
PEGAPegasystems Inc. | $5.8B | $35.18 | $35.60 | +1.2% | Buy | 14.5x | 24 |
CRMSalesforce, Inc. | $194.6B | $237.58 | $271.91 | +14.4% | Buy | 14.2x | 98 |
NICENICE Ltd. | $6.9B | $117.79 | $114.00 | -3.2% | Buy | 10.5x | 23 |
FIVNFive9, Inc. | $2.9B | $37.68 | $28.33 | -24.8% | Buy | 11.6x | 41 |
Quick answers to the most common questions about buying IBEX stock.
IBEX's consensus price target is $24, -43.7% below the current price of $42.66. The 6 analysts tracking IBEX see downside risk at present valuations.
IBEX has a consensus rating of "Hold" based on 6 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $24 implies -43.7% downside from current levels.
With a forward P/E of 12.1193x, IBEX trades at a relatively low valuation. The consensus target of $24 implies -43.7% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $29 for IBEX, while the most conservative target is $20. The consensus of $24 represents the median expectation. Our quantitative valuation model projects a bull case target of $66 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IBEX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IBEX stock forecast based on 6 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $20 (bear case) to $29 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $50, with bear/bull scenarios of $31/$66.
Our quantitative valuation model calculates IBEX's fair value at $50 (base case), with a bear case of $31 and bull case of $66. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
IBEX trades at a forward P/E ratio of 12.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on IBEX, with 0 Sell ratings and a price target of $24 (-43.7% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IBEX analyst price targets range from $20 to $29, a 38% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground. Our model's $31-$66 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.